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Abstract
Background: Aspiration pneumonia is an urgent health concern with high mortality and long hospitalization in
industrialized and aging countries. However, there is no information about the effectiveness of azithromycin (AZM)
for the treatment of aspiration pneumonia. This study investigated if AZM is effective for the treatment of aspiration
pneumonia.
Methods: Patients with aspiration pneumonia with no risk of multidrug-resistant pathogens were included in this
prospective study at Kishiwada City Hospital from December 2011 to June 2013. Patients were divided into the
ampicillin/sulbactam (ABPC/SBT) and AZM (intravenous injection) groups. The success rates of 1st-line antibiotic
therapy, mortality, length of hospital stay, and total antibiotic costs were compared.
Results: There were 81 and 36 patients in the ABPC/SBT and AZM groups, respectively. There was no significant
difference in the success rate of 1st-line antibiotics between the groups (74.1% vs. 75.0%, respectively, P = 1.000).
Mortality and hospitalization periods did not differ between the 2 groups (11.1% vs. 8.3%, P = 0.753, and 22.3 ±
7.3 days vs. 20.5 ± 8.1 days, P = 0.654, respectively). However, the total antibiotic costs were significantly lower in the
AZM group than the ABPC/SBT group (2.19 ± 1.65 × 10,000 yen vs. 2.94 ± 1.67 × 10,000 yen, respectively, P = 0.034).
The febrile period of the ABPC/SBT group was significantly shorter than that of the AZM group (P = 0.025).
Conclusions: In this small prospective non-randomized observational study, we found no statistically significant
differences in mortality or antibiotic failure in patients receiving AZM compared to ABPC/SBT for the treatment of
patients with aspiration pneumonia who require hospital admission and have no risk of drug-resistant pathogens.
Therefore, AZM may be another first choice of antibiotic treatment for patients with aspiration pneumonia when
they have no risk of multidrug-resistant pathogens.
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Background
Aspiration pneumonia is an urgent health concern with
high mortality and long hospitalization periods in indus-
trialized and aging countries [1]. In Japan’s rapidly aging
society, the mortality rate of pneumonia is 1,000 times
greater among people ≥85 years old than among young
adults irrespective of sex; moreover, pneumonia is the
leading cause of death of males ≥90 years old [2]. Most
cases of pneumonia in the elderly are reported to be as-
piration pneumonia [3]. Thus, aspiration pneumonia is a
crucial health issue, especially in Japan.
The frequent causative pathogens of aspiration pneumo-
nia include intraoral anaerobe-like periodontitis [4-6],
which should be covered by empiric antibiotic therapy for
aspiration pneumonia. Several guidelines state that patients
with aspiration pneumonia should receive β-lactams such
as ampicillin/sulbactam (ABPC/SBT) when they must be
admitted to hospitals and have no risk of multidrug-
resistant pathogens [2,7].
Azithromycin (AZM) is a macrolide antibiotic used ex-
tensively for the treatment of a wide range of infections
including CAP. AZM is effective not only against gram-
negative aerobic bacteria, but also against anaerobic bac-
teria [8]. Therefore, AZM is often used to treat periodontitis
[9]. However, there is no information about the effective-
ness of AZM for the treatment of aspiration pneumonia.
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Therefore, the present study investigated if AZM is effective
for the treatment of aspiration pneumonia.
Methods
Study design
This study was a prospective cohort study of patients with
pneumonia hospitalized at Kishiwada City Hospital (a 400-
bed community hospital in Kishiwada City, Osaka, Japan)
from December 2011 to June 2013. Patients with pneumo-
nia were classified as having community acquired pneumo-
nia (CAP), hospital acquired pneumonia (HAP), or nursing
and healthcare-associated pneumonia (NHCAP). According
to the Japanese Respiratory Society (JRS) guideline [2], pa-
tients with aspiration pneumonia among NHCAP group B
(who must be admitted to hospitals and have no risk of
multidrug-resistant pathogens) were subsequently selected
and categorized into the following groups on the basis of
the prescribed antibiotics: ABPC/SBT, AZM (intravenous
injection), and other. Treatment decisions for all study pa-
tients including type of antibiotic therapy administered
were not standardized and were made by physicians. We
compared the success rates of 1st-line antibiotic therapy,
mortality, length of hospital stay, and total antibiotic costs
among groups. This study was approved by the ethics com-
mittee of Kishiwada City Hospital and all participants pro-
vide written informed consent prior to participation on
admission.
Data collection
All data were collected prospectively. The following data
were recorded on admission: age, sex, sociodemographics,
Eastern Cooperative Oncology Group (ECOG) Perform-
ance Status, medical treatments, physical examination find-
ings, laboratory parameters, and chest radiograph findings.
CURB-65 and A-DROP were calculated on admission to
evaluate the severity of pneumonia [2,10]. CURB-65 con-
sisted of the following 5 score: 1) confusion of new onset,
2) blood urea nitrogen (BUN) >19 mg/dL, 3) respiratory
rate ≥30/min, 4) systolic blood pressure <90 mmHg or dia-
stolic blood pressure <60 mmHg, and 5) age ≥65 years.
A-DROP was a severity score modified from CURB-65 to
adjust Japanese healthcare system [11]. A-DROP con-
sisted of the following 5 score: 1) age (men ≥70 years,
women ≥75 years), 2) dehydration (BUN ≥21 mg/dL), 3) re-
spiratory failure (SpO2 ≤ 90% or PaO2 ≤ 60 Torr), 4) orienta-
tion disturbance, and 5) systolic blood pressure ≤90 mmHg
[12]. The clinical outcomes were the success rate of the
1st-line antibiotic therapy, in-hospital mortality, length of
hospital stay, and total antibiotic costs. Febrile periods
were also compared between groups.
Microbiological studies
Microbiological diagnosis was based on Gram stain and
culture samples (i.e., sputum, pleural fluid, or blood), rapid
urinary antigen test for Streptococcus pneumoniae (Binax-
NOW, Scarborough, MA, USA), and serum Mycoplasma
pneumoniae-specific IgM antibody. Gram staining was
performed by trained laboratory medical technologists,
and culture results were recorded semi-quantitatively. An
etiological diagnosis was established if any of the following
criteria were met: (1) moderate to heavy growth from
sputum samples suitable for evaluation (i.e., the presence
of >10 polymorphonuclear leukocytes and <10 squamous
cells per low-power field) with compatible Gram stain; (2)
positive culture in pleural fluid; (3) positive blood culture
if no other source was identified; (4) positive urinary anti-
gen test for S. pneumoniae; (5) positive rapid influenza
diagnostic test and other microbial etiology was negative.
Definitions
Pneumonia was defined as a new infiltrate together with
signs and symptoms of lower respiratory tract infection.
HAP was defined as pneumonia that occurred ≥48 h
after acute hospital admission. NHCAP was defined ac-
cording to the JRS guidelines [2] and included patients
who met at least one of the following criteria: (1) resi-
dence in a long-term care hospital or a nursing home;
(2) discharge from a hospital in the past 90 days; (3) eld-
erly or disabled person requiring care (i.e., performance
status 3 or 4); and (4) an outpatient who regularly re-
ceives infusion therapy (i.e., chronic dialysis, antibiotics,
cancer chemotherapy, and immunosuppressive drugs).
NHCAP group B met both of the following criteria: (1)
requirement of hospitalization and (2) no risk factors for
multidrug-resistant pathogens (i.e., no antibiotics within
the preceding 90 days, current tube feeding, or history
of methicillin-resistant Staphylococcus aureus [MRSA]
isolation). Patients were classified as CAP if they did not
meet the criteria for HAP or NHCAP. According to the
NHCAP guideline [2], aspiration pneumonia was defined
as being pneumonia that develops in patients in whom
dysphagia and aspiration is known to occur (or is strongly
suspected). The diagnosis of aspiration pneumonia was cat-
egorized into three groups; definitive cases (direct observa-
tion of aspiration by videofluoroscopic (VF) examination of
swallowing), probable cases (presence of functional dys-
phagia examined by bedside assessment of swallowing
function, arterial oxygen saturation monitoring during
swallowing, repetitive saliva swallowing test, water swal-
lowing test, simple swallowing provocation test), and pos-
sible cases (presence of risk factors for oropharyngeal
aspiration but without direct observation of aspiration nor
functional dysphagia). Swallowing function tests (VF and
bedside examinations) were conducted when the pneumo-
nia of the patient had been improved and started their
meal according to the physician’s decision (not to the doc-
umented criteria). Patients were excluded if they were con-
sidered to have other diseases that distinguished them
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from pneumonia at follow-up. Patients were also excluded
if their etiological diagnosis was influenza.
The clinical response to antibiotic treatment was de-
termined by assessing signs and symptoms of respiratory
infections as well as comparing the baseline and end-of-
treatment chest X-rays. Clinical efficacy was assessed
mainly based on the evaluation of body temperature,
WBC count, CRP, chest X-ray findings, signs and symp-
toms of pneumonia generally according to the criteria
for the evaluation of effectiveness in clinical efficacy rec-
ommended by Japanese Respiratory Society [2]. Total
antibiotic costs were calculated, including all intravenous
and oral antibiotics administered from admission to dis-
charge from our hospital.
MRSA, Pseudomonas aeruginosa, Acinetobacter species,
and extended-spectrum β-lactamase-producing Entero-
bacteriaceae were considered as multidrug-resistant path-
ogens on the basis of the 2005 IDSA/ATS guidelines.
Statistical analysis
Comparisons between groups were made using the χ2 test
or Fisher’s exact test for categorical variables and Student’s
t-test, and the Mann–Whitney U-test for continuous vari-
ables. Logistic regressions were performed to investigate
the clinical outcomes after adjustment for the severity
assessed by CURB-65 and ADROP. Febrile periods were
analyzed by the Kaplan–Meier method and compared by
the log-rank test. The level of statistical significance was
set at P < 0.05. All data were processed and analyzed using
SPSS version 20.0 (SPSS, Chicago, IL, USA)
Results
Patient characteristics
During the study period, 498 patients were admitted to
our hospital. The Kaplan–Meier plot of febrility is
shown in Figure 1. Briefly, 192 patients were diagnosed
as NHCAP group B, including 148 patients with aspir-
ation pneumonia. Then, 31 patients were excluded be-
cause they were treated with other antibiotics. Finally, 81
and 36 patients were included in the ABPC/SBT and
AZM groups, respectively. The baseline characteristics
of the subjects are shown in Table 1. There were no sig-
nificant differences between the AZM and ABPC/SBT
groups with respect to sex, age, severity, and diagnostic
category of aspiration pneumonia.
Pathogen distribution
Blood and sputum cultures were performed in 88
(75.2%) and 98 (89.7%) patients, respectively. Urinary
antigen tests were performed in 43 patients (36.8%). An
etiological diagnosis was established in 55 patients
(47.0%); among them, 43 (36.8%), 9 (7.7%), 5 (5.1%), and
1 (0.85%) were diagnosed on the basis of sputum cul-
tures, urinary antigen tests, blood culture, and pleural
effusion, respectively. There was no significant difference
in the frequency of an etiological diagnosis between the
ABPC/SBT and AZM groups (45.7% vs. 50.0%, respect-
ively, P = 0.692).
S. pneumoniae was the most frequent causative patho-
gen in both the ABPC/SBT and AZM groups, account-
ing for 21.0% and 25.0%, respectively (Table 1). All
isolated pneumococcal strains were penicillin sensitive
(minimum inhibitory concentration [MIC] ≤ 2 μg/mL),
according to the Clinical and Laboratory Standards Insti-
tute (CLSI) cut-offs [13]. The second most frequent
Figure 1 Kaplan–Meier Curve of Febrile Periods. The febrile
period of the ABPC/SBT group tended to be shorter than that of the
AZM group. ABPC/SBT: ampicillin/sulbactam; AZM, azithromycin.






Sex female/male 23/58 12/24 0.663
Age 78.9 ± 8.57 78.6 ± 9.15 0.874
Severity CURB-65 1.75 ± 0.80 1.69 ± 0.79 0.712




Definitive 8 (9.9%) 2 (5.6%) 0.722
Probable 69 (85.2%) 30 (83.3%) 0.787
Possible 4 (4.9%) 4 (11.1%) 0.248
Pathogen S. pneumoniae 17 (21.0%) 9 (25.0%) 0.637
H. influenzae 5 (6.2%) 2 (5.6%) 1.000
E. coli 2 (2.5%) 0 (0.0%) 1.000
P. aeruginosa 1 (1.2%) 1 (2.8%) 0.523
MSSA 9 (11.1%) 3 (8.3%) 0.753
MRSA 1 (1.2%) 0 (0.0%) 1.000
unknown 44 (52.3%) 18 (50.0%) 0.692
Analyzed by Fisher’s exact test or Mann–Whitney U-test.
ABPC/SBT, ampicillin/sulbactam.
AZM, azithromycin.
MSSA, methicillin-sensitive Staphylococcus aureus.
MRSA, methicillin-resistant Staphylococcus aureus.
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causative pathogen in both groups was methicillin-sensitive
Staphylococcus aureus. There was no significant difference
between the isolation rates of MRSA or P. aeruginosa
between groups.
Clinical outcomes
The clinical outcomes of the 2 groups are shown in
Table 2. There was no significant difference in the success
rate of 1st-line antibiotics between the ABPC/SBT and
AZM groups (74.1% vs. 75.0%, respectively, P = 1.000).
Mortality and hospitalization periods did not differ signifi-
cantly between groups (11.1% vs. 8.3%, P = 0.753; 22.3 ±
7.3 vs. 20.5 ± 8.1 days, P = 0.654, respectively). However,
the total antibiotic costs were significantly lower in
the AZM group than the ABPC/SBT group (2.19 ± 1.65 ×
10,000 yen vs. 2.94 ± 1.67 × 10,000 yen, respectively,
P = 0.034). There are two patients with positive serum
Mycoplasma pneumoniae IgM antibody in the AZM
group. On the other hand, there was no patient in the
ABPC/SBT group. Excluding the two patients in the AZM
group, we compared the clinical outcome again. There
was no significant difference in the success rate of 1st-line
antibiotics between the ABPC/SBT and AZM groups
(74.1% vs. 74.3%, respectively, P = 1.000). Mortality and
hospitalization periods did not differ significantly between
groups (11.1% vs. 8.8%, P = 1.00; 22.3 ± 7.3 vs. 20.7 ±
8.0 days, P = 0.674, respectively). The total antibiotic costs
were significantly lower in the AZM group than the
ABPC/SBT group (2.13 ± 1.62 × 10,000 yen vs. 2.94 ±
1.67 × 10,000 yen, respectively, P = 0.024).
The adjusted odds ratios (OR) of the success rate of
1st-line antibiotics and mortality were calculated by lo-
gistic regressions. The OR for the success rate of 1st-line
antibiotics comparing ABPC/SBT group to AZM group
were 0.901 (95% confidential interval (CI): 0.360 – 2.258)
and 0.887 (95% CI: 0.352 – 2.234) after adjustment by
CURB-65 and ADROP, respectively. The OR for mortality
comparing ABPC/SBT group to AZM group were 1.297
(95% CI: 0.310 – 5.433) and 1.258 (95% CI: 0.293 – 5.408)
after adjustment by CURB-65 and ADROP, respectively.
Patients received ABPC/SBT (2:1) 1.5 g intravenously
every 8 h for 7–14 days. For patients with decreased
estimated glomerular filtration rate (eGFR), the q8h dos-
age of ABPC/SBT was adjusted as follows: patients with
an eGFR 15–29 and <14 mL/min were administered
1.5 g every 12 and 24 h, respectively. Patients received
AZM 500 mg intravenously every 24 h for 5 days,
followed by switching to AZM 500 mg orally every 24 h
for 3 days. In patients successfully treated with 1st-line
antibiotics, ABPC/SBT was administered for an average
of 9.03 ± 1.80 days. In 57 of the 60 successful cases,
ABPC/SBT was continued until the end of treatment
without switching to oral antibiotics. On the other
hand, AZM was administered for 5 days in all success-
fully treated cases. In 11 of 24 successful cases, intra-
venous AZM was switched to oral AZM (500 mg/day
for 3 days).
The Kaplan–Meier curves of the febrile periods are
shown in Figure 1. The log-rank test showed the febrile
period of the ABPC/SBT group was significantly shorter
than that of the AZM group (P = 0.025).
Discussion
The present study is the first to demonstrate the nonin-
feriority of AZM to ABPC/SBT for the treatment of pa-
tients with aspiration pneumonia who need to be
admitted to hospitals and have no risk of multidrug-
resistant pathogens (i.e., NHCAP group B). The success
rates of 1st-line antibiotic therapy, mortality rates, and
hospitalization duration were similar between patients
treated with AZM and ABPC/SBT. However, the total
antibiotic costs were significantly lower in patients
treated with AZM than ABPC/SBT. The febrile period
of the ABPC/SBT group was significantly shorter than
that of the AZM group.
Pneumonia has traditionally been classified as either
community or hospital acquired (CAP and HAP, re-
spectively) depending whether it developed in outpatient
or inpatient settings. The joint guidelines proposed by
the American Thoracic Society (ATS) and the Infectious
Diseases Society of America (IDSA) define a new cat-
egory of pneumonia: healthcare-associated pneumonia
(HCAP) [7]. Many subsequent studies from various coun-
tries revealed that HCAP is a clinically heterogeneous dis-
ease and that the populations of patients with HCAP vary
among countries depending on the healthcare environment
including social health insurance systems. In order to ad-
just to Japan’s healthcare system, HCAP was changed to
“nursing and healthcare-associated pneumonia” (NHCAP)
in 2011 by the Japanese Respiratory Society (JRS) [2]. Large
proportions of NHCAP and HCAP cases are aspiration
pneumonia [3].
The pathogens of aspiration pneumonia are reported
to include not only common bacteria of CAP such as
S. pneumoniae, but also intraoral anaerobic bacteria such
as Fusobacterium, Peptostreptococcus, Bacteroides, and






Success rate of 1st-line antibiotics 60 (74.1%) 24 (75.0%) 1.000
Mortality 9 (11.1%) 3 (8.3%) 0.753
Hospitalization period (days) 22.3 ± 7.3 20.5 ± 8.1 0.654
Total antibiotic costs (×10,000 yen) 2.94 ± 1.67 2.19 ± 1.65 0.034
Analyzed by Fisher’s exact test or Mann–Whitney U-test.
ABPC/SBT, ampicillin/sulbactam.
AZM, azithromycin.
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Prevotella [4-6]. Therefore, HCAP and NHCAP guidelines
recommend administering penicillin with β-lactamase
inhibitor (ABPC/SBT or piperacillin/tazobactam) or car-
bapenems (imipenem/cilastatin or meropenem) [2,7]. Be-
cause these β-lactams must be administered 3 times or
more per day according to pharmacokinetic/pharmacody-
namic theory [14], patients with aspiration pneumonia re-
quire hospitalization. On the other hand, AZM only
requires once daily administration. Therefore, the present
study suggests outpatient parenteral antimicrobial therapy
(OPAT) could be administered to patients with aspiration
pneumonia if their dysphagia is mild such that they are
able eat a normal diet. OPAT for patients with aspiration
pneumonia might provide several benefits not only to the
patients themselves, but to society as well [15]. OPAT
could reduce the costs of healthcare systems as well as
hospitalization-induced psychological stress in patients.
Nevertheless, an interventional study is required to test
these hypotheses.
In the present study, Kaplan–Meier analysis revealed
that the ABPC/SBT group had a significantly shorter fe-
brile period than that of the AZM group. This may be
partly due to the different antimicrobial activities of
ABPC/SBT and AZM: ABPC/SBT has bactericidal activ-
ity, whereas AZM has bacteriostatic activity [16-18].
Therefore, ABPC/SBT rapidly ameliorates the inflamma-
tion of bacterial pneumonia by killing pathological bac-
teria. However, this does not mean that ABPC/SBT is
more effective than AZM in cases of severe pneumonia.
Combination therapy is administered for severe pneu-
monia, in which macrolide-containing combinations im-
prove mortality rate [19]. Moreover, these effects have
been demonstrated even in cases involving pneumonia
caused by macrolide-resistant pathogens. Several studies
indicate that the anti-inflammatory effects of macrolide
could account for the improved mortality rate.
As mentioned above, total antibiotic costs were signifi-
cantly lower in the AZM group than the ABPC/SBT
group. In the AZM group, AZM 500 mg was adminis-
tered intravenously for 5 days before switching to oral
administration of the same dose for 3 days. On the other
hand, in the ABPC/SBT group, intravenous administra-
tion of ABPC/SBT was required to continue until the
end of antibiotic therapy. This is because the approved
dose for the oral administration of penicillin with a
β-lactamase inhibitor is insufficient for the treatment of
pneumonia in Japan. Therefore, ABPC/SBT was admin-
istered intravenously until the end of treatment in the
present study. Thus, the present results demonstrate AZM
is comparatively cost effective. However, randomized con-
trolled studies are required to confirm this finding.
Recent reports demonstrate S. pneumoniae has high re-
sistance to macrolides worldwide. In Japan, clarithromycin-
resistant strains are reported to make up over 50% of all of
S. pneumoniae strains [20]. Furthermore, the proportion of
AZM-resistant strains is reported to be as high as that of
clarithromycin-resistant strains. In the present study, the
resistance rate of isolated S. pneumoniae to clarithromycin
was as high as 68.0% (17 out of 25). However, the success
rate of intravenous AZM was acceptably high. Thus, there
is a discrepancy between the efficacy of clarithromycin
in vitro and the effectiveness of intravenous AZM in vivo.
A previous study reports similar results, i.e., intravenous-
to-oral azithromycin therapy demonstrated excellent clin-
ical and bacteriological effects on moderate-to-severe
pneumococcal pneumonia despite a high MIC and resist-
ance gene development [21]. This discrepancy can be ex-
plained by the unique properties of AZM, including
phagocyte delivery, extremely long half-life, inhibitory ef-
fect on S. pneumoniae pneumolysin production, and anti-
inflammatory and immunomodulatory activities [22-25].
This study has several limitations that should be men-
tioned. First, the present study was not a randomized
controlled study but an observational study. Many con-
founders may lie hidden. However, the administration of
either AZM or ABPC/SBT was comparable and the se-
lection bias of antibiotics (i.e., AZM vs. ABPC/SBT) may
be small, because the baseline characteristics were very
similar between the two groups, including the severity of
pneumonia and pathogens. Second, no discharge or anti-
biotic withdrawal criteria were defined, which might
have influenced hospitalization duration and total anti-
biotic costs. Third, anaerobic cultures for sputum sam-
ple were not performed in the present study, though
anaerobic bacteria are regarded as important causative
pathogens for aspiration pneumonia. Forth, serum anti-
bodies for Chlamydophila were not measured in the
present study, though potent activities of AZM against
atypical pathogens including Chlamydophila might have
influenced the clinical outcomes.
AZM is appropriate for aspiration pneumonia for the
following reasons. First, AZM could cover most causative
pathogens of aspiration pneumonia from gram-positive
cocci such as S. pneumoniae to anaerobic bacteria, which
are common pathogens of periodontitis. Second, OPAT
could be used to treat aspiration pneumonia by selecting
intravenous antibiotics with AZM. Third, the unique ef-
fects of AZM may play beneficial roles in patients with
aspiration pneumonia [25].
Conclusions
In this small prospective non-randomized observational
study, we found no statistically significant differences in
mortality or antibiotic failure in patients receiving AZM
compared to ABPC/SBT. Therefore, AZM may be an-
other first choice of antibiotic treatment for patients
with aspiration pneumonia who require hospitalization
and have no risk of multi-drug resistant pathogens.
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